{"id":444,"date":"2020-08-20T05:51:47","date_gmt":"2020-08-20T05:51:47","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=444"},"modified":"2020-08-20T05:51:47","modified_gmt":"2020-08-20T05:51:47","slug":"11-aug-2020-hydroxychloroquine-lopinavir-r-no-statistically-significant-differences-with-hcq-or-lpv-rtv","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/11-aug-2020-hydroxychloroquine-lopinavir-r-no-statistically-significant-differences-with-hcq-or-lpv-rtv\/","title":{"rendered":"(11 Aug 2020) Hydroxychloroquine, Lopinavir\/R- No statistically significant differences with HCQ or LPV\/RTV"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\">Hydroxychloroquine versus lopinavir\/ritonavir in severe COVID-19 patients : Results from a real-life patient cohort<\/p>\n<p class=\"\">https:\/\/doi.org\/10.1007\/s00508-020-01720-y<\/p>\n<p class=\"\">Of 156 patients (41% female) with a median age of 72 years (IQR 55.25-81) admitted to our department, 67 patients fulfilled the inclusion criteria (20 received HCQ, 47 LPV\/RTV). Groups were comparable regarding most baseline characteristics. Median time from symptom onset to treatment initiation was 8 days and was similar between the groups (p= 0.727). There was no significant difference (HCQ vs. LPV\/RTV) in hospital mortality (15% vs. 8.5%, p= 0.418), ICU admission rate (20% vs. 12.8%, p= 0.470) and length of stay (9 days vs. 11 days, p= 0.340). A PCR negativity from nasopharyngeal swabs was observed in approximately two thirds of patients in both groups. Side effects led to treatment discontinuation in 15% of patients in the LPV\/RTV group. CONCLUSION: No statistically significant differences were observed in outcome parameters in patients treated with HCQ or LPV\/RTV but patients in the LPV\/RTV group showed a numerically lower hospital mortality rate. Additionally, in comparison to other studies we demonstrated a lower mortality in patients treated with LPV\/RTV despite having similar patient groups, perhaps due to early initiation of treatment.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Hydroxychloroquine versus lopinavir\/ritonavir in severe COVID-19 patients : Results from a real-life patient cohort https:\/\/doi.org\/10.1007\/s00508-020-01720-y Of 156 patients (41% female) with a median age of 72 years (IQR 55.25-81) admitted to our department, 67 patients fulfilled the inclusion criteria (20&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/11-aug-2020-hydroxychloroquine-lopinavir-r-no-statistically-significant-differences-with-hcq-or-lpv-rtv\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(11 Aug 2020) Hydroxychloroquine, Lopinavir\/R- No statistically significant differences with HCQ or LPV\/RTV&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,9,12],"tags":[10,41],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/444"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=444"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/444\/revisions"}],"predecessor-version":[{"id":448,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/444\/revisions\/448"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=444"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=444"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=444"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}